Cure My Disease

Don't miss your cure!

 Log in / Sign up

First human test for promising blood cancer treatment

NCT ID NCT05936359

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study to test the safety and find the right dose of a new drug called INCA033989. It will be given alone or combined with an existing drug (ruxolitinib) to 225 people with certain blood cancers called myeloproliferative neoplasms. The main goal is to see how well the body tolerates the drug and identify any serious side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aou Policlinico S. Orsola-Malpighi

    RECRUITING

    Bologna, 40138, Italy

  • Azienda Ospedaliero-Universitaria Careggi (Aouc)

    RECRUITING

    Florence, 50134, Italy

  • Chu Nimes

    RECRUITING

    Nîmes, 30029, France

  • Fondazione Irccs Ca Granda Ospedale Maggiore

    RECRUITING

    Milan, 20122, Italy

  • Guys and St Thomas Nhs Foundation Trust

    RECRUITING

    London, SE1 9RT, United Kingdom

  • Hopital Maisonneuve-Rosemont, Montreal, Qc

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

  • Hospital Saint Louis

    RECRUITING

    Paris, 75010, France

  • Hospital Universitari I Politecnic La Fe

    RECRUITING

    Valencia, 46026, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Institut Bergonie

    RECRUITING

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Kagoshima University Hospital

    RECRUITING

    Kagoshima, 890-8520, Japan

  • Mie University Hospital

    RECRUITING

    Tsu, 514-0001, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Chiba-ken, 277-0882, Japan

  • Nippon Medical School Hospital

    RECRUITING

    Tokyo, 113-8603, Japan

  • Odense University Hospital

    WITHDRAWN

    Odense C, 05000, Denmark

  • Osaka Metropolitan University Hospital

    RECRUITING

    Osaka, 545-8586, Japan

  • Peter Maccallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 03000, Australia

  • Princess Margaret Cancer Center

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 05000, Australia

  • Royal Brisbane and Women'S Hospital

    RECRUITING

    Herston, Queensland, 04029, Australia

  • Sjaellands Universitetshospital

    RECRUITING

    Roskilde, 04000, Denmark

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 03004, Australia

  • The Christie Nhs Foundation Trust Uk

    RECRUITING

    Manchester, M20 4BV, United Kingdom

  • Universitatsklinikum Halle (Saale)

    RECRUITING

    Halle, 06120, Germany

  • University Medical Center Rwth Aachen

    RECRUITING

    Aachen, 52074, Germany

  • University of Oxford

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Universitätsklinikum Ulm

    RECRUITING

    Ulm, 89081, Germany

  • Vejle Hospital

    RECRUITING

    Vejle, 07100, Denmark

Conditions

Explore the condition pages connected to this study.

MYELOPROLIFERATIVE NEOPLASMS